AU2024204581B2 - Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease - Google Patents

Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease

Info

Publication number
AU2024204581B2
AU2024204581B2 AU2024204581A AU2024204581A AU2024204581B2 AU 2024204581 B2 AU2024204581 B2 AU 2024204581B2 AU 2024204581 A AU2024204581 A AU 2024204581A AU 2024204581 A AU2024204581 A AU 2024204581A AU 2024204581 B2 AU2024204581 B2 AU 2024204581B2
Authority
AU
Australia
Prior art keywords
levodopa
chch2ch
derivative
derivatives
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2024204581A
Other languages
English (en)
Other versions
AU2024204581A1 (en
Inventor
Leema Reddy Peddareddy Gari
Manoj K. Mishra
Deven Patel
H. Rajan SHARMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dynamic Biologics Inc
Original Assignee
Dynamic Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynamic Biologics Inc filed Critical Dynamic Biologics Inc
Publication of AU2024204581A1 publication Critical patent/AU2024204581A1/en
Application granted granted Critical
Publication of AU2024204581B2 publication Critical patent/AU2024204581B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2024204581A 2023-07-05 2024-07-02 Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease Active AU2024204581B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/218,372 US12036199B1 (en) 2023-07-05 2023-07-05 Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of Parkinson's disease
US18/218,372 2023-07-05

Publications (2)

Publication Number Publication Date
AU2024204581A1 AU2024204581A1 (en) 2025-01-23
AU2024204581B2 true AU2024204581B2 (en) 2025-07-31

Family

ID=91759631

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024204581A Active AU2024204581B2 (en) 2023-07-05 2024-07-02 Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease

Country Status (10)

Country Link
US (2) US12036199B1 (enExample)
EP (1) EP4595956A1 (enExample)
JP (1) JP7617334B1 (enExample)
KR (1) KR102846332B1 (enExample)
CN (1) CN119264002B (enExample)
AU (1) AU2024204581B2 (enExample)
CA (1) CA3244296C (enExample)
IL (1) IL325508A (enExample)
MX (1) MX2026000058A (enExample)
WO (1) WO2025010073A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120119464B (zh) * 2025-04-18 2025-12-05 浙江理工大学 一种自清洁型亲水聚四氟乙烯纤维膜的制备方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022098A1 (en) * 2007-08-11 2009-02-19 Proximagen Ltd. Amino acid derivatives
WO2014139161A1 (en) * 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
WO2020264460A1 (en) * 2019-06-28 2020-12-30 Dynamic Biologics Inc. Levodopa polymeric conjugates, formulations thereof, and their uses for the treatment of parkinson's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH562199A5 (enExample) * 1970-10-30 1975-05-30 Hoffmann La Roche
AT324316B (de) * 1973-06-27 1975-08-25 Lannacher Heilmittel Verfahren zur herstellung von neuen racemischen oder optisch aktiven phenylalaninestern
EP1596808A4 (en) * 2003-02-07 2007-04-04 Yissum Res Dev Co L-DOPA AMID DERIVATIVES AND THEIR USE
US8207369B2 (en) * 2008-02-11 2012-06-26 Ramot At Tel-Aviv University Ltd. Conjugates for treating neurodegenerative diseases and disorders
EP3925624A4 (en) * 2019-02-12 2023-01-18 University of Tsukuba LEVODOPA DERIVATIVE AND USE THEREOF

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022098A1 (en) * 2007-08-11 2009-02-19 Proximagen Ltd. Amino acid derivatives
WO2014139161A1 (en) * 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
WO2020264460A1 (en) * 2019-06-28 2020-12-30 Dynamic Biologics Inc. Levodopa polymeric conjugates, formulations thereof, and their uses for the treatment of parkinson's disease

Also Published As

Publication number Publication date
CA3244296C (en) 2026-04-28
MX2026000058A (es) 2026-05-04
JP2025013734A (ja) 2025-01-27
US12036199B1 (en) 2024-07-16
KR20250008693A (ko) 2025-01-15
EP4595956A1 (en) 2025-08-06
CA3244296A1 (enExample) 2026-04-24
WO2025010073A1 (en) 2025-01-09
IL325508A (en) 2026-02-01
CN119264002B (zh) 2025-10-17
KR102846332B1 (ko) 2025-08-18
CN119264002A (zh) 2025-01-07
JP7617334B1 (ja) 2025-01-17
US20250114319A1 (en) 2025-04-10
AU2024204581A1 (en) 2025-01-23
NZ812405A (en) 2025-07-25

Similar Documents

Publication Publication Date Title
KR102209353B1 (ko) 파킨슨 병 치료 방법
JP5976111B2 (ja) メチルフェニデート−プロドラッグ、その製造法及び使用法
US6696600B2 (en) L-DOPA ethyl ester salts and uses thereof
JPH06508135A (ja) 抗変性活性剤としての置換ｎ−カルボキシアルキルペプチジル誘導体
JP2018514516A (ja) 水溶性ｌ‐ドーパエステル
CA3244296C (en) Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease
WO1992012952A1 (en) Malic acid derivatives and compositions for the treatment of psoriasis
AU2020303907B2 (en) Levodopa polymeric conjugates, formulations thereof, and their uses for the treatment of Parkinson's disease
US20220096370A1 (en) High penetration composition and uses thereof
KR20230155508A (ko) 레보도파-티로신 접합체를 포함하는 안정화된 액체 조성물 및 그의 용도
US12533417B2 (en) L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders
CN1115145C (zh) 药理活性β－氨基酸的可耐受性的改进
WO2007040535A1 (en) Use of polyamine analogs for treatment and prevention of intestinal polyps
WO2020178810A1 (en) Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
WO2006086773A2 (en) Polyamine analogs as modulators of cell migration and cell motility
CN106928308B (zh) 蓑衣莲酮的前药及其应用
JP2002528387A (ja) 脂肪酸誘導体
JPS6354322A (ja) 副作用の軽減されたペネム型またはカルバペネム型抗生物質製剤
US20230248696A1 (en) Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
NZ812405B2 (en) Levodopa fatty acid derivatives, formulations thereof, and their uses for the treatment of parkinson's disease
WO2024233985A1 (en) Biodegradable oligomers and polymers for oligonucleotide and gene delivery
GR1010487B (el) Συνθεσεις που περιλαμβανουν τιγεκυκλινη
CN116964069A (zh) 包含左旋多巴-酪氨酸缀合物的稳定化的液体组合物及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)